Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.
about
Patient perspectives on fluticasone-vilanterol versus other corticosteroid combination products for the treatment of asthmaClinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of lifeSpotlight on fluticasone furoate/vilanterol trifenatate for the once-daily treatment of asthma: design, development and place in therapyEase-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older.Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre studyEffect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPDRecent advances in COPD disease management with fixed-dose long-acting combination therapies.Umeclidinium for the treatment of chronic obstructive pulmonary disease.Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.Dry powder inhalers in COPD, lung inflammation and pulmonary infections.Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.Fluticasone furoate/vilanterol: a review of its use in patients with asthma.Inhalation drug delivery devices: technology update.Long-acting muscarinic antagonists.Developments in inhaled combination therapies: patent activity 2013-2014.The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience.Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.Fixed-Dose combination of the inhaled corticosteroid and long-acting beta2-agonist therapy in adults with persistent asthma.Vilanterol trifenatate for the treatment of COPD.Inhalation devices: from basic science to practical use, innovative vs generic products.Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination.Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma.The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world.Effectiveness of Nurse-Driven Inhaler Education on Inhaler Proficiency and Compliance Among Obstructive Lung Disease Patients: A Quasi-Experimental Study.A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI.Maintenance inhaler preference, attribute importance, and satisfaction in prescribing physicians and patients with asthma, COPD, or asthma-COPD overlap syndrome consulting for routine care.Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.Satisfaction, preference and error occurrence of three dry powder inhalers as assessed by a cohort naïve to inhaler operation.Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol.Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences
P2860
Q26743444-E265E86A-0BD1-4364-99A3-866C2207EBEBQ26801134-AEAD8031-0AE6-4D04-8FDF-441F698A2D65Q28074802-950D26FB-B246-4EB8-9E92-BA6962861028Q34710866-5D0E9972-0758-4AFE-8CFF-D25136EC9252Q35556510-091A9635-17FA-4006-8E45-4144C9FD49E2Q36388416-7EB92F8F-A85B-454D-B5F9-1AAD54CB8108Q36388505-F2FEA17C-447A-4CAB-B849-AB80B6494939Q36388517-632CC78A-684D-4A77-AED9-6826405F0660Q37200540-813E27BF-97D9-45A2-8C90-B44BC31694E3Q37437109-C415A6FD-3B0B-453B-8D76-CF7EB3CCEBDCQ37614090-D81AD83B-BD2D-4BC9-907D-F5C4AA0A0593Q38209841-8A08DE8D-F0E5-4E17-973E-D7844828E250Q38259862-93C61E1E-5E05-455A-9077-67D603648543Q38266325-8D4E3534-3935-4ECB-91DA-CD431693680DQ38267333-23EC3458-F70E-4D30-95D8-7E14C5C9046FQ38284373-781D2977-5055-494C-8080-51364EE3FA6BQ38342870-B79701BC-B254-4C37-A3C0-D9FE2892C4C4Q38364686-BF096036-C396-4268-B572-1A44D1139FD4Q38537326-0029CADB-F8F2-4842-8BC6-1DE97A260FC9Q38541928-8C33A331-B4DD-4B08-B52D-2043B4909A58Q38669520-AF969FA1-A320-4F29-977F-6902DA496BC0Q38692883-4ADDBFFB-98E3-4254-995C-465CEA297418Q38707759-BDEF38BA-4FF9-4402-A037-7CBDC7C0EC72Q38824916-FD752740-A975-4742-B29F-50AC0EDD8BFCQ38856654-32E796F8-5956-437E-A169-C7C6D1DB25B2Q39773324-69D154C6-3F87-4A12-9935-D550578155B8Q42697426-17EDFAD6-83B6-4395-809B-D8815FE11D6FQ49281529-C06901D0-0A60-49D6-AA2F-093360183E71Q50848095-B1D60A7B-F7A9-452B-BF21-8B0272FE64F5Q51666077-916726BE-357F-40C2-A471-6305EDC13F5EQ54958121-084FD5E0-EA17-4699-BDBB-318BBEB9F651Q55120067-C0A80072-0096-4807-A811-3FD4C160D17CQ55301329-BA3EC000-2F62-458D-9F29-78F8EDC67BBCQ55360310-8D15A801-C8FF-4516-9A93-464A1549C72FQ58784324-9A54D7BC-F0E7-49D2-8D31-2D8635C80BEB
P2860
Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Qualitative assessment of attr ...... e therapy for asthma and COPD.
@ast
Qualitative assessment of attr ...... e therapy for asthma and COPD.
@en
type
label
Qualitative assessment of attr ...... e therapy for asthma and COPD.
@ast
Qualitative assessment of attr ...... e therapy for asthma and COPD.
@en
prefLabel
Qualitative assessment of attr ...... e therapy for asthma and COPD.
@ast
Qualitative assessment of attr ...... e therapy for asthma and COPD.
@en
P2093
P2860
P356
P1476
Qualitative assessment of attr ...... e therapy for asthma and COPD.
@en
P2093
Henrik Svedsater
Karl Garrill
Mark W Woepse
Peter Dale
Richard Walker
P2860
P2888
P356
10.1186/1471-2466-13-72
P577
2013-12-07T00:00:00Z
P5875
P6179
1024593319